ASSESSMENT OF CORONARY ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH FIVE YEAR HISTORY OF MYOCARDIAL INFARCTION DEPENDING ON THE STATIN THERAPY COMPLIANCE
Aim. To study the coronary atherosclerosis progression in patients with 5-year history of myocardial infarction (MI) depending on the statin therapy compliance. Material and methods. Patients (n=31) with a five year history of MI were involved into the study. Patients were divided into two groups de...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim. To study the coronary atherosclerosis progression in patients with 5-year history of myocardial infarction (MI) depending on the statin therapy compliance. Material and methods. Patients (n=31) with a five year history of MI were involved into the study. Patients were divided into two groups depending on the statin therapy compliance during 5 years after MI: group 1 — patients with high compliance, group 2 — patients with low compliance. Assessment of the coronary angiography and lipid profile was performed first time in 2005–2006 during hospital treatment for MI and after 5 years again. Results. Increase in the proportion of patients with two and three coronary vessel disease was found after 5 years of observation, despite the high rate of percutaneous coronary intervention (77.4%) and hypolipidemic therapy. Hemodynamically significant restenosis was found in 11.8% (group 1) and 21.4% (group 2) of patients. Target total cholesterol level was reached only in 42.9% and 11.8% of patients in group 1 and 2, respectively. The target level of low density cholesterol was achieved in no one patient. Conclusion. The findings suggest that in patients with 5-year history of MI coronary atherosclerosis progresses regardless of the statin therapy compliance. |
|---|---|
| ISSN: | 1819-6446 2225-3653 |